Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PANK3 | Q9H999 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.46 |
| ▸ | DTYMK | P23919 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | JAK1 | P23458 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31726812 | 0.87 | MEN1 (0.41) | PANK3MEN1KMT2AATMPOLB | |
| SCHEMBL14190953 | 0.86 | MEN1 (0.50) | MEN1KMT2APOLBGPR119DTYMK | |
| SCHEMBL12557699 | 0.85 | KMT2A (0.69) | MEN1KMT2AATMPOLBRAB9A | |
| SCHEMBL5064405 | 0.83 | KMT2A (0.60) | MEN1KMT2AATMSMN1; SMN2HTT | |
| SCHEMBL16211006 | 0.80 | KMT2A (0.52) | PANK3MEN1KMT2AATMGPR119 | |
| SCHEMBL3613404 | 0.80 | L3MBTL1 (0.56) | PANK3MEN1KMT2AATMPOLB | |
| SCHEMBL24095092 | 0.80 | KMT2A (0.61) | MEN1KMT2A | |
| SCHEMBL6195498 | 0.80 | GPR119 (0.46) | MEN1KMT2AATMPOLBRAB9A | |
| SCHEMBL3982606 | 0.79 | GPR119 (0.50) | MEN1KMT2APOLBGPR119SMN1; SMN2 | |
| SCHEMBL29495589 | 0.79 | GPR119 (0.50) | MEN1KMT2APOLBGPR119SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080103123-A1 | New compounds | BIOVITRUM (SE) | 2008-05-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080103123-A1 | New compounds | GPR119, GPR139, GPR180 | PANK3 3308/4885MEN1 2409/4885KMT2A 4721/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.